Top Tweets for #GiOnc

4 days ago

⭐️”I think we are going to bend the mortality curve in #pancreaticcancer”. 👉CEO of @RevMedicines joined the @OncBrothers to discuss the story behind Daraxonrasib approval and the company’s mission. #OncTwitter #HemOnc #gism #pcsm #GIOnc #MedTwitter 🎥👇 https://t.co/5LrTBEx9K2

0

5

0

542

Jun Gong, MD @jgong15

4 days ago

@_backtableONC knows how to put on a production 👏👏 pleasure sitting down w/two #KOLs & friends in #GIonc @IbrahimSahinMD1 @AGangiMD to talk #periop #CRC Download the Backtable app❗️ @AaronFrittsMD More #GIonc ep coming❗️ @ronanhsieh @DaniCastilloMD @Ahn_Daniel_Onc @AlgazeMD

BackTable Tumor Board

@_backtableONC

5 days ago

Structured exercise matched the disease-free survival (DFS) benefit of adjuvant oxaliplatin. 🏃 Dr. Jun Gong (@jgong15), Dr. Ibrahim Sahin (@IbrahimSahinMD1) and Dr. Alexandra Gangi (@AGangiMD) on CHALLENGE, ATOMIC, ctDNA after liver resection, and transplant for unresectable colorectal cancer (CRC). Watch the full episode on the BackTable App: https://t.co/wD9zBNWcJZ #ONC82 #Oncology #ColorectalCancer #GIOncology @CedarsSinai @UMRogelCancer @ASCO @myESMO

0

5

3

1

1K

0

6

4

0

695

11 days ago

⭐️New @NEJM: Colonoscopy interval after high-risk adenoma removal 🎯5-yr vs 3-yr first surveillance ✅5-yr CRC incidence: 0.77% vs 0.82% ✅Stage at diagnosis similar 🔑starting surveillance at 5 yrs was noninferior to 3 yrs #CRC #GIOnc #gism #OncTwitter https://t.co/rD9Hvt60LV

1

8

3

1

706

DAVA Oncology

@DAVAOnc

12 days ago

Optimally managing intrahepatic cholangiocarcinoma, reviewed by Dr. Lipika Goyal from @StanfordMed at #DAVAGI: targeting FGFR2 fusions (pemigatinib, futibatinib, lirafugratinib, tinengotinib), IDH1 mutations (ivosidenib), and HER2 (zanidatamab, T-DXd). #GIOnc

DAVAOnc's tweet photo. Optimally managing intrahepatic cholangiocarcinoma, reviewed by Dr. Lipika Goyal from @StanfordMed at #DAVAGI: targeting FGFR2 fusions (pemigatinib, futibatinib, lirafugratinib, tinengotinib), IDH1 mutations (ivosidenib), and HER2 (zanidatamab, T-DXd). #GIOnc https://t.co/jyqcIOh58j

0

2

0

1

251

DAVA Oncology

@DAVAOnc

12 days ago

Recent phase 3 results in colorectal cancer, from Dr. @kanwal_raghav (@UTMDAnderson) at #DAVAGI: ATOMIC (atezolizumab + FOLFOX in dMMRstage III), BREAKWATER (encorafenib + chemo in BRAF V600E 1L), KRYSTAL-10 (adagrasib + cetuximab), and STELLAR-303. #GIOnc

DAVAOnc's tweet photo. Recent phase 3 results in colorectal cancer, from Dr. @kanwal_raghav (@UTMDAnderson) at #DAVAGI: ATOMIC (atezolizumab + FOLFOX in dMMRstage III), BREAKWATER (encorafenib + chemo in BRAF V600E 1L), KRYSTAL-10 (adagrasib + cetuximab), and STELLAR-303. #GIOnc https://t.co/Ar3b00S4XL

0

4

1

3

216

DAVA Oncology

@DAVAOnc

12 days ago

Targeting RAS in Pancreatic Cancer: At #DAVAGI, Dr. Channing Der (@cjder23) from @UNC_SOM traced 45 years from KRAS/HRAS discovery (1981) to daraxonrasib FDA approval (Aug 2026), spanning FTIs, ERK inhibitors, G12C drugs, and tri-complex on-state inhibitors. #GIOnc

DAVAOnc's tweet photo. Targeting RAS in Pancreatic Cancer: At #DAVAGI, Dr. Channing Der (@cjder23) from @UNC_SOM traced 45 years from KRAS/HRAS discovery (1981) to daraxonrasib FDA approval (Aug 2026), spanning FTIs, ERK inhibitors, G12C drugs, and tri-complex on-state inhibitors. #GIOnc https://t.co/XooOiYbjQS

0

3

0

1

127

Sawyer Bawek, DO @sawyer_bawek

14 days ago

🚨 ANNOUNCEMENT | FDA Breakthrough Therapy Designation 👉RASONQUE (daraxonrasib) + gemcitabine/nab-paclitaxel has received BTD for first-line metastatic PDAC. #PDAC #PancreaticCancer #GIOnc #OncTwitter @RevMedicines #gism #RAS #Oncology 🔗Link: https://t.co/fAV9LYMWhD

2

12

10

1

940

OncLive.com

@OncLive

25 days ago

Meet the chairs of the Ruesch Center Symposium: John L. Marshall, MD @marshalj23 @LombardiCancer, Nilo S. Azad, MD @HopkinsMedicine, Timothy L. Cannon, MD @InovaHealth, and Petr F. Hausner, MD @UMmedschool. Register: https://t.co/ppiIoe6iWl @MedStarGUH @RueschCenter #GIOnc #RueschCenterSymposium

OncLive's tweet photo. Meet the chairs of the Ruesch Center Symposium: John L. Marshall, MD @marshalj23 @LombardiCancer, Nilo S. Azad, MD @HopkinsMedicine, Timothy L. Cannon, MD @InovaHealth, and Petr F. Hausner, MD @UMmedschool.

Register: https://t.co/ppiIoe6iWl

@MedStarGUH @RueschCenter #GIOnc #RueschCenterSymposium

0

5

2

941

25 days ago

⭐️ Patient-friendly breakdown of #RASolute302 and what #Daraxonrasib means for patients is now available @OncUpdates! #OncTwitter #MedTwitter #HemOnc #MedX #GIOnc #gism #PDAC #PancreaticCancer #CancerResearch #MedEd #Oncology #PatientEducation @HemOncFellows #Viral #Cancer

26 days ago

⭐️Patient Education: New targeted pill for #PancreaticCancer What #FDA approved #Daraxonrasib means for patients: ✅Median Overall Survival doubled ✅Oral pill ⚠️Rash, mouth sores,+diarrhea #OncTwitter #GIOnc #gism #MedX 🔗Patient-friendly breakdown👇 https://t.co/VcO6DUe8Ap

1

5

0

1K

0

9

3

0

1K

26 days ago

⭐️Patient Education: New targeted pill for #PancreaticCancer What #FDA approved #Daraxonrasib means for patients: ✅Median Overall Survival doubled ✅Oral pill ⚠️Rash, mouth sores,+diarrhea #OncTwitter #GIOnc #gism #MedX 🔗Patient-friendly breakdown👇 https://t.co/VcO6DUe8Ap

1

5

0

1K

28 days ago

@aakonc @OncBrothers @FDADrugs @BijoyTelivala @RenoHemonc @dr_yakupergun @GlopesMd @doctorpemm @GIcancerDoc @RahulBanerjeeMD @TarekHaykal1 @DrChoueiri I'm loving seeing new transformation in our space #GIonc

0

4

0

55

30 days ago

⭐️@rachnatshroff discusses w/@OncBrothers side effects for the recent #FDA approval of #Daraxonrasib for metastatic #PancreaticCancer #OncTwitter #GIOnc #gism #MedTwitter #CancerResearch #cancer #MedEd #MedX @DrShubhamPant @EileenMOReilly 🔗Full video👇 https://t.co/ItYlfiWw8T

0

10

6

1

836

about 1 month ago

@TimothyJBrownMD @NateraOncology Congrats brother. Mandatory experience is needed in NE Indiana. Come train @bejmedonc and I a bit. #GIonc

1

2

0

302

about 1 month ago

🚨GAME CHANGER in #PancreaticCancer now #FDA Approved @EileenMOReilly discusses w/@OncBrothers efficacy of #Daraxonrasib in #RAS mutations. #OncTwitter #GIOnc #gism #MedTwitter #CancerResearch #cancer @DrShubhamPant @rachnatshroff 🔗 Full video👇 https://t.co/ItYlfiWw8T

0

10

6

3

1K

about 1 month ago

⭐️Dr.Ko addresses who will be a candidate for the recent @FDA approval Daraxonrasib. #OncTwitter #MedTwitter #MedX #PDAC #PancreaticCancer #GIOnc #TargetedTherapy #PrecisionOncology #gism #HemOnc #MedEd

3 months ago

⭐️Practice Changing in #Metastatic #PancreaticCancer, Who Will Be A Candidate for Daraxonrasib 🤔 👉Dr.Andrew Ko discusses this 🔑 question with @OncBrothers #OncTwitter #pcsm #gism #MedTwitter #ASCO #CancerResearch #Cancer #MedEd @RoswellPark @WilmotCancer @UCSFCancer

0

8

7

1

1K

0

4

3

1

714

Rutika Mehta @rutikamehtaMD

about 1 month ago

When research from #ASCO26 hits real life in my community with record time. So thrilled to have #daraxonrasib as a groundbreaking targeted therapy in #pancsm #GIonc.

2

18

6

1

753

about 1 month ago

📢FDA approval of zanidatamab + chemotherapy ± tislelizumab in the 1L setting represents an important advance and ushers in a new era for HER2-directed therapy in GEA. Congratulations to the investigators, patients, and teams who made this possible! #GastricCancer #HER2 #GIOnc

1

19

4

3

1K

OncLive.com

@OncLive

about 1 month ago

The 17th Annual Ruesch Center Symposium returns Nov 19-21, bringing together clinicians, researchers, patients, and caregivers to advance GI cancer care. Register: https://t.co/esLFWBxHw4 @LombardiCancer @MedStarGUH @RueschCenter #GIOnc #RueschCenterSymposium

OncLive's tweet photo. The 17th Annual Ruesch Center Symposium returns Nov 19-21, bringing together clinicians, researchers, patients, and caregivers to advance GI cancer care.

Register: https://t.co/esLFWBxHw4

@LombardiCancer @MedStarGUH @RueschCenter #GIOnc #RueschCenterSymposium https://t.co/VUuHJDcSip

0

2

3

0

681